{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T18:13:50Z","timestamp":1785521630760,"version":"3.56.0"},"reference-count":68,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T00:00:00Z","timestamp":1777939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T00:00:00Z","timestamp":1777939200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004331","name":"Johnson and Johnson","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004331","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Ther"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s40744-026-00849-y","type":"journal-article","created":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T17:41:27Z","timestamp":1778002887000},"page":"899-930","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Golimumab for the Treatment of Rheumatoid Arthritis: A Narrative Review of Pivotal Randomized Trials and Real-World Studies"],"prefix":"10.1007","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5668-4497","authenticated-orcid":false,"given":"Uta","family":"Kiltz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7593-3065","authenticated-orcid":false,"given":"Yi-Ming","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Rubbert-Roth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-3687-5964","authenticated-orcid":false,"given":"Sergio","family":"Fonseca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3505-6314","authenticated-orcid":false,"given":"Jos\u00e9","family":"Antunes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arun","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-4055-2686","authenticated-orcid":false,"given":"Richard","family":"Milek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-2192-338X","authenticated-orcid":false,"given":"Jordan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5556-4618","authenticated-orcid":false,"given":"Jeffrey A.","family":"Sparks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,5]]},"reference":[{"issue":"3","key":"849_CR1","doi-asserted-by":"publisher","first-page":"532","DOI":"10.4103\/aam.aam_11_24","volume":"24","author":"D Deka","year":"2025","unstructured":"Deka D. Pathogenesis and current treatment strategies in rheumatoid arthritis: a systematic review article. Ann Afr Med. 2025;24(3):532\u20139.","journal-title":"Ann Afr Med"},{"issue":"6","key":"849_CR2","doi-asserted-by":"publisher","DOI":"10.3390\/clinpract15060103","volume":"15","author":"AL Vlad","year":"2025","unstructured":"Vlad AL, Popazu C, Lescai AM, Voinescu DC, Balt\u0103 AA\u0218. Where do we stand in the management of rheumatoid arthritis ahead of EULAR\/ACR 2025? Clin Pract. 2025;15(6):103.","journal-title":"Clin Pract"},{"issue":"4","key":"849_CR3","first-page":"427","volume":"66","author":"A Di Matteo","year":"2024","unstructured":"Di Matteo A, Emery P. Rheumatoid arthritis: a review of the key clinical features and ongoing challenges of the disease. Panminerva Med. 2024;66(4):427\u201342.","journal-title":"Panminerva Med"},{"issue":"3","key":"849_CR4","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.509","volume":"5","author":"Y Gao","year":"2024","unstructured":"Gao Y, Zhang Y, Liu X. Rheumatoid arthritis: pathogenesis and therapeutic advances. MedComm. 2024;5(3):e509.","journal-title":"MedComm"},{"issue":"1","key":"849_CR5","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.hcl.2024.07.002","volume":"41","author":"S Tancer","year":"2025","unstructured":"Tancer S, Wallace BI. Advances in the medical treatment of rheumatoid arthritis. Hand Clin. 2025;41(1):11\u201323.","journal-title":"Hand Clin"},{"issue":"10","key":"849_CR6","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1016\/j.clinthera.2010.09.003","volume":"32","author":"EG Boyce","year":"2010","unstructured":"Boyce EG, Halilovic J, Stan-Ugbene O. Golimumab: review of the efficacy and tolerability of a recently approved tumor necrosis factor-\u03b1 inhibitor. Clin Ther. 2010;32(10):1681\u2013703.","journal-title":"Clin Ther"},{"issue":"6","key":"849_CR7","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1002\/pro.3407","volume":"27","author":"M Ono","year":"2018","unstructured":"Ono M, Horita S, Sato Y, Nomura Y, Iwata S, Nomura N. Structural basis for tumor necrosis factor blockade with the therapeutic antibody golimumab. Protein Sci. 2018;27(6):1038\u201346.","journal-title":"Protein Sci"},{"issue":"5","key":"849_CR8","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1517\/14712598.2014.896334","volume":"14","author":"H Marotte","year":"2014","unstructured":"Marotte H, Cimaz R. Etanercept - TNF receptor and IgG1 Fc fusion protein: is it different from other TNF blockers? Expert Opin Biol Ther. 2014;14(5):569\u201372.","journal-title":"Expert Opin Biol Ther"},{"issue":"8","key":"849_CR9","doi-asserted-by":"publisher","first-page":"2272","DOI":"10.1002\/art.24638","volume":"60","author":"P Emery","year":"2009","unstructured":"Emery P, Fleischmann RM, Moreland LW, et al. Golimumab, a human anti-tumor necrosis factor alpha monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis. Arthritis Rheum. 2009;60(8):2272\u201383.","journal-title":"Arthritis Rheum"},{"issue":"6","key":"849_CR10","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1136\/ard.2008.099010","volume":"68","author":"EC Keystone","year":"2009","unstructured":"Keystone EC, Genovese MC, Klareskog L, et al. Golimumab, a human antibody to tumour necrosis factor-\u03b1 given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD study. Ann Rheum Dis. 2009;68(6):789\u201396.","journal-title":"Ann Rheum Dis"},{"issue":"9685","key":"849_CR11","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/S0140-6736(09)60506-7","volume":"374","author":"JS Smolen","year":"2009","unstructured":"Smolen JS, Kay J, Doyle MK, for GO-AFTER Study Investigators. Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial. Lancet. 2009;374(9685):210\u201321 (Erratum in: Lancet. 2009;374(9699):1422).","journal-title":"Lancet"},{"issue":"3","key":"849_CR12","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1136\/annrheumdis-2012-201411","volume":"72","author":"ME Weinblatt","year":"2013","unstructured":"Weinblatt ME, Bingham CO 3rd, Mendelsohn AM, et al. Intravenous golimumab is effective in patients with active rheumatoid arthritis despite methotrexate therapy with responses as early as week 2: results of the phase III, randomised, multicentre, double-blind, placebo-controlled GO-FURTHER trial. Ann Rheum Dis. 2013;72(3):381\u20139.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"849_CR13","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1002\/acr.22759","volume":"68","author":"P Emery","year":"2016","unstructured":"Emery P, Fleischmann RM, Strusberg I, et al. Efficacy and safety of subcutaneous golimumab in methotrexate-naive patients with rheumatoid arthritis: five-year results of a randomized clinical trial. Arthritis Care Res (Hoboken). 2016;68(6):744\u201352.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"6","key":"849_CR14","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1136\/ard.2009.116319","volume":"69","author":"E Keystone","year":"2010","unstructured":"Keystone E, Genovese MC, Klareskog L, et al. Golimumab in patients with active rheumatoid arthritis despite methotrexate therapy: 52-week results of the GO-FORWARD study. Ann Rheum Dis. 2010;69(6):1129\u201335.","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"849_CR15","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.3899\/jrheum.120584","volume":"40","author":"EC Keystone","year":"2013","unstructured":"Keystone EC, Genovese MC, Hall S, et al. Golimumab in patients with active rheumatoid arthritis despite methotrexate therapy: results through 2 years of the GO-FORWARD study extension. J Rheumatol. 2013;40(7):1097\u2013103.","journal-title":"J Rheumatol"},{"issue":"2","key":"849_CR16","doi-asserted-by":"publisher","first-page":"298","DOI":"10.3899\/jrheum.150712","volume":"43","author":"EC Keystone","year":"2016","unstructured":"Keystone EC, Genovese MC, Hall S, et al. Safety and efficacy of subcutaneous golimumab in patients with active rheumatoid arthritis despite methotrexate therapy: final 5-year results of the GO-FORWARD trial. J Rheumatol. 2016;43(2):298\u2013306.","journal-title":"J Rheumatol"},{"issue":"10","key":"849_CR17","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1136\/annrheumdis-2011-200956","volume":"71","author":"JS Smolen","year":"2012","unstructured":"Smolen JS, Kay J, Landew\u00e9 RB, et al. Golimumab in patients with active rheumatoid arthritis who have previous experience with tumour necrosis factor inhibitors: results of a long-term extension of the randomised, double-blind, placebo-controlled GO-AFTER study through week 160. Ann Rheum Dis. 2012;71(10):1671\u20139.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"849_CR18","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-015-0516-6","volume":"17","author":"JS Smolen","year":"2015","unstructured":"Smolen JS, Kay J, Doyle M, et al. Golimumab in patients with active rheumatoid arthritis after treatment with tumor necrosis factor \u03b1 inhibitors: findings with up to five years of treatment in the multicenter, randomized, double-blind, placebo-controlled, phase 3 GO-AFTER study. Arthritis Res Ther. 2015;17(1):14.","journal-title":"Arthritis Res Ther"},{"issue":"12","key":"849_CR19","doi-asserted-by":"publisher","first-page":"2152","DOI":"10.1136\/annrheumdis-2013-203742","volume":"73","author":"ME Weinblatt","year":"2014","unstructured":"Weinblatt ME, Westhovens R, Mendelsohn AM, et al. Radiographic benefit and maintenance of clinical benefit with intravenous golimumab therapy in patients with active rheumatoid arthritis despite methotrexate therapy: results up to 1 year of the phase 3, randomised, multicentre, double blind, placebo-controlled GO-FURTHER trial. Ann Rheum Dis. 2014;73(12):2152\u20139.","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"849_CR20","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1002\/acr.22556","volume":"67","author":"CO Bingham 3rd","year":"2015","unstructured":"Bingham CO 3rd, Mendelsohn AM, Kim L, et al. Maintenance of clinical and radiographic benefit with intravenous golimumab therapy in patients with active rheumatoid arthritis despite methotrexate therapy: week-112 efficacy and safety results of the open-label long-term extension of a phase III, double-blind, randomized, placebo-controlled trial. Arthritis Care Res (Hoboken). 2015;67(12):1627\u201336.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"12","key":"849_CR21","doi-asserted-by":"publisher","first-page":"3397","DOI":"10.1007\/s10067-023-06760-z","volume":"42","author":"CLJ Weinstein","year":"2023","unstructured":"Weinstein CLJ, Meehan AG, Lin J, Briscoe SD, Govoni M. Long-term golimumab persistence: five-year treatment retention data pooled from pivotal phase III clinical trials in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. Clin Rheumatol. 2023;42(12):3397\u2013405.","journal-title":"Clin Rheumatol"},{"issue":"5","key":"849_CR22","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1002\/art.30263","volume":"63","author":"P Emery","year":"2011","unstructured":"Emery P, Fleischmann R, van der Heijde D, et al. The effects of golimumab on radiographic progression in rheumatoid arthritis: results of randomized controlled studies of golimumab before methotrexate therapy and golimumab after methotrexate therapy. Arthritis Rheum. 2011;63(5):1200\u201310.","journal-title":"Arthritis Rheum"},{"issue":"11","key":"849_CR23","doi-asserted-by":"publisher","first-page":"1968","DOI":"10.1136\/ard.2010.146068","volume":"70","author":"PG Conaghan","year":"2011","unstructured":"Conaghan PG, Emery P, \u00d8stergaard M, et al. Assessment by MRI of inflammation and damage in rheumatoid arthritis patients with methotrexate inadequate response receiving golimumab: results of the GO-FORWARD trial. Ann Rheum Dis. 2011;70(11):1968\u201374.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"849_CR24","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.3899\/jrheum.111195","volume":"39","author":"MC Genovese","year":"2012","unstructured":"Genovese MC, Han C, Keystone EC, et al. Effect of golimumab on patient-reported outcomes in rheumatoid arthritis: results from the GO-FORWARD study. J Rheumatol. 2012;39(6):1185\u201391.","journal-title":"J Rheumatol"},{"issue":"6","key":"849_CR25","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.3899\/jrheum.130864","volume":"41","author":"CO Bingham 3rd","year":"2014","unstructured":"Bingham CO 3rd, Weinblatt M, Han C, et al. The effect of intravenous golimumab on health-related quality of life in rheumatoid arthritis: 24-week results of the phase III GO-FURTHER trial. J Rheumatol. 2014;41(6):1067\u201376.","journal-title":"J Rheumatol"},{"key":"849_CR26","doi-asserted-by":"publisher","DOI":"10.1186\/s41927-020-00145-4","volume":"4","author":"P Rahman","year":"2020","unstructured":"Rahman P, Baer P, Keystone E, et al. Long-term effectiveness and safety of infliximab, golimumab and golimumab-IV in rheumatoid arthritis patients from a Canadian prospective observational registry. BMC Rheumatol. 2020;4:46.","journal-title":"BMC Rheumatol"},{"issue":"3","key":"849_CR27","first-page":"642","volume":"42","author":"M Govoni","year":"2024","unstructured":"Govoni M, Batalov A, Boumpas DT, et al. Real-world effectiveness of golimumab in the treatment of patients with active rheumatoid arthritis, psoriatic arthritis, or axial spondyloarthritis who failed initial TNF-\u03b1 inhibitor therapy: a pooled analysis of European prospective observational studies (the GO-BEYOND program). Clin Exp Rheumatol. 2024;42(3):642\u201350.","journal-title":"Clin Exp Rheumatol"},{"issue":"4","key":"849_CR28","doi-asserted-by":"publisher","first-page":"282","DOI":"10.4103\/injr.injr_210_22","volume":"18","author":"BD Pandey","year":"2023","unstructured":"Pandey BD, Krishnamurthy V, Kumar U, et al. Safety and efficacy of golimumab in rheumatoid arthritis: a prospective, multicenter, real-world study from India. Indian J Rheumatol. 2023;18(4):282\u20138.","journal-title":"Indian J Rheumatol"},{"issue":"4","key":"849_CR29","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1007\/s00296-021-05073-1","volume":"42","author":"D Psaltis","year":"2022","unstructured":"Psaltis D, Settas L, Georgiadis A, et al. The effects of golimumab on patient centric outcomes amongst rheumatoid arthritis patients in Greece. The GO-Q study Rheumatol Int. 2022;42(4):639\u201350.","journal-title":"The GO-Q study Rheumatol Int"},{"issue":"4","key":"849_CR30","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1007\/s40744-021-00354-4","volume":"8","author":"JR Curtis","year":"2021","unstructured":"Curtis JR, Chakravarty SD, Black S, et al. Incidence of infusion reactions and clinical effectiveness of intravenous golimumab versus infliximab in patients with rheumatoid arthritis: the real-world AWARE study. Rheumatol Ther. 2021;8(4):1551\u201363.","journal-title":"Rheumatol Ther"},{"issue":"1","key":"849_CR31","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1080\/14397595.2017.1325058","volume":"28","author":"M Kanbori","year":"2018","unstructured":"Kanbori M, Suzuka H, Yajima T, et al. Postmarketing surveillance evaluating the safety and effectiveness of golimumab in Japanese patients with rheumatoid arthritis. Mod Rheumatol. 2018;28(1):66\u201375.","journal-title":"Mod Rheumatol"},{"issue":"3","key":"849_CR32","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1080\/14397595.2020.1797283","volume":"31","author":"H Shimizu","year":"2021","unstructured":"Shimizu H, Kobayashi H, Kanbori M, Ishii Y. Clinical response among golimumab-treated Japanese patients with rheumatoid arthritis by number of previous biologic therapies: real-world evidence from post-hoc analysis of post-marketing surveillance data. Mod Rheumatol. 2021;31(3):566\u201374.","journal-title":"Mod Rheumatol"},{"issue":"6","key":"849_CR33","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2017-021082","volume":"8","author":"K Kr\u00fcger","year":"2018","unstructured":"Kr\u00fcger K, Burmester GR, Wassenberg S, Bohl-B\u00fchler M, Thomas MH. Effectiveness and safety of golimumab in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis under real-life clinical conditions: non-interventional GO-NICE study in Germany. BMJ Open. 2018;8(6):e021082.","journal-title":"BMJ Open"},{"issue":"1","key":"849_CR34","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1007\/s00296-018-4180-4","volume":"39","author":"K Kr\u00fcger","year":"2019","unstructured":"Kr\u00fcger K, Burmester GR, Wassenberg S, Bohl-B\u00fchler M, Thomas MH. Patient-reported outcomes with golimumab in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: non-interventional study GO-NICE in Germany. Rheumatol Int. 2019;39(1):131\u201340.","journal-title":"Rheumatol Int"},{"issue":"2","key":"849_CR35","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1007\/s40744-020-00204-9","volume":"7","author":"K Kr\u00fcger","year":"2020","unstructured":"Kr\u00fcger K, Burmester GR, Wassenberg S, Thomas MH. Golimumab as the first-, second-, or at least third-line biologic agent in patients with rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis: post hoc analysis of a noninterventional study in Germany. Rheumatol Ther. 2020;7(2):371\u201382.","journal-title":"Rheumatol Ther"},{"issue":"8","key":"849_CR36","doi-asserted-by":"publisher","first-page":"2319","DOI":"10.1007\/s10067-022-06116-z","volume":"41","author":"J Tesser","year":"2022","unstructured":"Tesser J, Lin I, Shiff NJ, et al. Improvement in disease activity among patients with rheumatoid arthritis who switched from intravenous infliximab to intravenous golimumab in the ACR RISE registry. Clin Rheumatol. 2022;41(8):2319\u201327.","journal-title":"Clin Rheumatol"},{"issue":"2","key":"849_CR37","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1097\/JCMA.0000000000000673","volume":"85","author":"CC Wang","year":"2022","unstructured":"Wang CC, Tseng KS, Tsao YP, et al. Real-world effectiveness and safety of golimumab in rheumatoid arthritis treatment: a two-center study in Taiwan. J Chin Med Assoc. 2022;85(2):175\u201382.","journal-title":"J Chin Med Assoc"},{"issue":"1","key":"849_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2020.07.011","volume":"88","author":"F Iannone","year":"2021","unstructured":"Iannone F, Favalli EG, Caporali R, et al. Golimumab effectiveness in biologic inadequate responding patients with rheumatoid arthritis, psoriatic arthritis and spondyloarthritis in real-life from the Italian registry GISEA. Jt Bone Spine. 2021;88(1):105062.","journal-title":"Jt Bone Spine"},{"key":"849_CR39","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.881943","volume":"9","author":"C Dejaco","year":"2022","unstructured":"Dejaco C, Mueller T, Zamani O, et al. A prospective study to evaluate the impact of golimumab therapy on work productivity and activity, and quality of life in patients with rheumatoid arthritis, psoriasis arthritis and axial spondyloarthritis in a real life setting in Austria. The GO-ACTIVE Study. Front Med. 2022;9:881943.","journal-title":"Front Med"},{"issue":"3","key":"849_CR40","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1007\/s40744-023-00533-5","volume":"10","author":"CO Bingham 3rd","year":"2023","unstructured":"Bingham CO 3rd, Black S, Shiff NJ, Xu S, Langholff W, Curtis JR. Response to treatment with intravenous golimumab or infliximab in rheumatoid arthritis patients: PROMIS results from the real-world observational Phase 4 AWARE study. Rheumatol Ther. 2023;10(3):659\u201378.","journal-title":"Rheumatol Ther"},{"issue":"3","key":"849_CR41","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1007\/s40744-023-00539-z","volume":"10","author":"M Miyashiro","year":"2023","unstructured":"Miyashiro M, Ishii Y, Miyazaki C, Shimizu H, Masuda J. A real-world claims database study assessing long-term persistence with golimumab treatment in patients with rheumatoid arthritis in Japan. Rheumatol Ther. 2023;10(3):615\u201334.","journal-title":"Rheumatol Ther"},{"issue":"3","key":"849_CR42","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1111\/1756-185X.14281","volume":"25","author":"T Mutoh","year":"2022","unstructured":"Mutoh T, Nagai T, Shirai T, Okazaki S, Sato H, Fujii H. Predictive factors for retention of golimumab over a median 4-year duration in Japanese patients with rheumatoid arthritis in a real-world setting: a retrospective study and literature review. Int J Rheum Dis. 2022;25(3):335\u201343.","journal-title":"Int J Rheum Dis"},{"issue":"5","key":"849_CR43","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1093\/mr\/roab126","volume":"32","author":"K Takabayashi","year":"2022","unstructured":"Takabayashi K, Ando F, Ikeda K, et al. Trend in prescription and treatment retention of molecular-targeted drugs in 121,131 Japanese patients with rheumatoid arthritis: a population-based real-world study. Mod Rheumatol. 2022;32(5):857\u201365.","journal-title":"Mod Rheumatol"},{"issue":"3","key":"849_CR44","doi-asserted-by":"publisher","first-page":"537","DOI":"10.55563\/clinexprheumatol\/zizo0l","volume":"39","author":"RM Flipo","year":"2021","unstructured":"Flipo RM, Tubach F, Goupille P, et al. Real-life persistence of golimumab in patients with chronic inflammatory rheumatic diseases: results of the 2-year observational GO-PRACTICE study. Clin Exp Rheumatol. 2021;39(3):537\u201345.","journal-title":"Clin Exp Rheumatol"},{"issue":"1","key":"849_CR45","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1002\/msc.1684","volume":"21","author":"M Pombo-Su\u00e1rez","year":"2023","unstructured":"Pombo-Su\u00e1rez M, Seoane-Mato D, D\u00edaz-Gonz\u00e1lez F, et al. Long-term retention of golimumab treatment in clinical practice in a large cohort of patients with rheumatoid arthritis, axial spondyloarthritis and psoriatic arthritis. Musculoskelet Care. 2023;21(1):189\u201397.","journal-title":"Musculoskelet Care"},{"issue":"11","key":"849_CR46","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1111\/1756-185X.14423","volume":"25","author":"JY Huang","year":"2022","unstructured":"Huang JY, Leong PY, Ker A, Chen HH, Wei JC. The long-term persistence of tumor necrosis factor inhibitors in patients with moderate to severe immune-mediated rheumatic diseases: a nation-wide, population-based real-world study. Int J Rheum Dis. 2022;25(11):1295\u2013305.","journal-title":"Int J Rheum Dis"},{"issue":"1","key":"849_CR47","doi-asserted-by":"publisher","first-page":"e150","DOI":"10.1097\/RHU.0000000000001695","volume":"28","author":"B Serrano-Benavente","year":"2022","unstructured":"Serrano-Benavente B, Valor L, Del R\u00edo BT, et al. Long-term retention rate of golimumab in patients with rheumatoid arthritis, psoriatic arthritis, and spondyloarthritis in a real-life setting. J Clin Rheumatol. 2022;28(1):e150\u20135.","journal-title":"J Clin Rheumatol"},{"issue":"10","key":"849_CR48","doi-asserted-by":"publisher","first-page":"841","DOI":"10.2217\/imt-2020-0296","volume":"13","author":"S Akar","year":"2021","unstructured":"Akar S, Kalyoncu U, Dalkilic E, et al. GO-BEYOND: a real-world study of persistence of golimumab in patients with axial spondyloarthritis and rheumatoid arthritis in Turkey. Immunotherapy. 2021;13(10):841\u201350.","journal-title":"Immunotherapy"},{"key":"849_CR49","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m2288","volume":"370","author":"K Janke","year":"2020","unstructured":"Janke K, Biester K, Krause D, et al. Comparative effectiveness of biological medicines in rheumatoid arthritis: systematic review and network meta-analysis including aggregate results from reanalysed individual patient data. BMJ. 2020;370:m2288.","journal-title":"BMJ"},{"key":"849_CR50","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.814429","volume":"13","author":"B He","year":"2022","unstructured":"He B, Li Y, Luo WW, et al. The risk of adverse effects of TNF-\u03b1 inhibitors in patients with rheumatoid arthritis: a network meta-analysis. Front Immunol. 2022;13:814429.","journal-title":"Front Immunol"},{"key":"849_CR51","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.927179","volume":"13","author":"CT de Castro","year":"2022","unstructured":"de Castro CT, de Queiroz MJ, Albuquerque FC, et al. Real-world effectiveness of biological therapy in patients with rheumatoid arthritis: systematic review and meta-analysis. Front Pharmacol. 2022;13:927179.","journal-title":"Front Pharmacol"},{"key":"849_CR52","doi-asserted-by":"crossref","unstructured":"Schneeberger EE, Felquer MLA, Citera G, et al. Long-term persistence of biological agents in the treatment of patients with rheumatoid arthritis: a systematic literature review and meta-analysis. Clin Rheumatol. 2025 (Epub ahead of print. Erratum in: Clin Rheumatol. 2025 Dec 3).","DOI":"10.1007\/s10067-025-07700-9"},{"issue":"3","key":"849_CR53","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10030509","volume":"10","author":"PC Taylor","year":"2021","unstructured":"Taylor PC, Atzeni F, Balsa A, Gossec L, M\u00fcller-Ladner U, Pope J. The key comorbidities in patients with rheumatoid arthritis: a narrative review. J Clin Med. 2021;10(3):509.","journal-title":"J Clin Med"},{"issue":"1","key":"849_CR54","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s13075-022-02753-6","volume":"24","author":"ME Husni","year":"2022","unstructured":"Husni ME, Deodhar A, Schwartzman S, et al. Pooled safety results across phase 3 randomized trials of intravenous golimumab in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. Arthritis Res Ther. 2022;24(1):73.","journal-title":"Arthritis Res Ther"},{"issue":"9","key":"849_CR55","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.3899\/jrheum.2022-1283","volume":"50","author":"L Bessette","year":"2023","unstructured":"Bessette L, Rahman P, Kelsall J, et al. Real-world incidence and determinants of infection in patients with rheumatoid arthritis treated with golimumab after a median follow-up time of 27 months. J Rheumatol. 2023;50(9):1121\u20136.","journal-title":"J Rheumatol"},{"key":"849_CR56","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1376262","volume":"15","author":"Z Jiang","year":"2024","unstructured":"Jiang Z, Zou Y, Li G, Zhao S, Zhang W. Comparisons of infection events associated with tumor necrosis factor inhibitors in patients with inflammatory arthritis: a systematic review and network meta-analysis. Front Pharmacol. 2024;15:1376262.","journal-title":"Front Pharmacol"},{"issue":"12","key":"849_CR57","doi-asserted-by":"publisher","first-page":"2229","DOI":"10.3899\/jrheum.150057","volume":"42","author":"JW Ai","year":"2015","unstructured":"Ai JW, Zhang S, Ruan QL, et al. The risk of tuberculosis in patients with rheumatoid arthritis treated with tumor necrosis factor-\u03b1 antagonist: a metaanalysis of both randomized controlled trials and registry\/cohort studies. J Rheumatol. 2015;42(12):2229\u201337.","journal-title":"J Rheumatol"},{"issue":"4","key":"849_CR58","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1111\/1756-185X.13401","volume":"22","author":"T Watanabe","year":"2019","unstructured":"Watanabe T, Fukae J, Fukaya S, et al. Incidence and risk factors for reactivation from resolved hepatitis B virus in rheumatoid arthritis patients treated with biological disease-modifying antirheumatic drugs. Int J Rheum Dis. 2019;22(4):574\u201382.","journal-title":"Int J Rheum Dis"},{"issue":"1","key":"849_CR59","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-022-02871-1","volume":"24","author":"S Jeong","year":"2022","unstructured":"Jeong S, Choi S, Park SM, Kim J, Ghang B, Lee EY. Incident and recurrent herpes zoster for first-line bDMARD and tsDMARD users in seropositive rheumatoid arthritis patients: a nationwide cohort study. Arthritis Res Ther. 2022;24(1):180.","journal-title":"Arthritis Res Ther"},{"issue":"3","key":"849_CR60","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1136\/annrheumdis-2014-206624","volume":"74","author":"C Roubille","year":"2015","unstructured":"Roubille C, Richer V, Starnino T, et al. The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis. Ann Rheum Dis. 2015;74(3):480\u20139.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"849_CR61","doi-asserted-by":"publisher","DOI":"10.2144\/fsoa-2018-0108","volume":"5","author":"F Atzeni","year":"2019","unstructured":"Atzeni F, Gianturco L, Boccassini L, Sarzi-Puttini P, Bonitta G, Turiel M. Noninvasive imaging methods for evaluating cardiovascular involvement in patients with rheumatoid arthritis before and after anti-TNF drug treatment. Future Science OA. 2019;5(6):FSO396.","journal-title":"Future Science OA"},{"issue":"9","key":"849_CR62","doi-asserted-by":"publisher","first-page":"483","DOI":"10.2217\/fon-2019-0722","volume":"16","author":"S Morand","year":"2020","unstructured":"Morand S, Staats H, Creeden JF, et al. Molecular mechanisms underlying rheumatoid arthritis and cancer development and treatment. Future Oncol. 2020;16(9):483\u201395.","journal-title":"Future Oncol"},{"issue":"1","key":"849_CR63","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-90996-z","volume":"15","author":"J Song","year":"2025","unstructured":"Song J, Kim SR, Kim YJ, Park SJ, Jeong S, Park SM. Risk of hematologic malignancies in psoriasis and rheumatoid arthritis patients using long term TNF-\u03b1 inhibitors: a retrospective nationwide study. Sci Rep. 2025;15(1):7949.","journal-title":"Sci Rep"},{"issue":"6","key":"849_CR64","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1080\/03009742.2021.1875040","volume":"50","author":"JE Gehin","year":"2021","unstructured":"Gehin JE, Warren DJ, Syversen SW, et al. Serum golimumab concentration and anti-drug antibodies are associated with treatment response and drug survival in patients with inflammatory joint diseases: data from the NOR-DMARD study. Scand J Rheumatol. 2021;50(6):445\u201354.","journal-title":"Scand J Rheumatol"},{"issue":"6","key":"849_CR65","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22062922","volume":"22","author":"K Romanowska-Pr\u00f3chnicka","year":"2021","unstructured":"Romanowska-Pr\u00f3chnicka K, Felis-Giemza A, Olesi\u0144ska M, Wojdasiewicz P, Paradowska-Gorycka A, Szukiewicz D. The role of TNF-\u03b1 and anti-TNF-\u03b1 agents during preconception, pregnancy, and breastfeeding. Int J Mol Sci. 2021;22(6):2922.","journal-title":"Int J Mol Sci"},{"issue":"8","key":"849_CR66","doi-asserted-by":"publisher","DOI":"10.1002\/pds.5878","volume":"33","author":"P Karlsson","year":"2024","unstructured":"Karlsson P, Gembert K, Esslinger S, et al. Pregnancy and infant outcomes after prenatal exposure to golimumab in Denmark, Finland, and Sweden 2006-2019. Pharmacoepidemiol Drug Saf. 2024;33(8):e5878.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"4","key":"849_CR67","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.1240","volume":"12","author":"M Otero-Lobato","year":"2024","unstructured":"Otero-Lobato M, Adeyemo A, Higley M, Lomax KG, Geldhof A, Esslinger S. Exposure to golimumab during pregnancy: results from the Company\u2019s global safety database. Pharmacol Res Perspect. 2024;12(4):e1240.","journal-title":"Pharmacol Res Perspect"},{"issue":"6","key":"849_CR68","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1016\/j.ard.2025.02.023","volume":"84","author":"L R\u00fcegg","year":"2025","unstructured":"R\u00fcegg L, Pluma A, Hamroun S, et al. EULAR recommendations for use of antirheumatic drugs in reproduction, pregnancy, and lactation: 2024 update. Ann Rheum Dis. 2025;84(6):910\u201326.","journal-title":"Ann Rheum Dis"}],"container-title":["Rheumatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-026-00849-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40744-026-00849-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-026-00849-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T17:05:01Z","timestamp":1785517501000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40744-026-00849-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,5]]},"references-count":68,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["849"],"URL":"https:\/\/doi.org\/10.1007\/s40744-026-00849-y","relation":{},"ISSN":["2198-6576","2198-6584"],"issn-type":[{"value":"2198-6576","type":"print"},{"value":"2198-6584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,5]]},"assertion":[{"value":"9 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Uta Kiltz has received grant and research support and consultancy fees from AbbVie, Amgen, Biocad, Biogen, Bristol-Myers Squibb, Chugai, Eli Lilly, Fresenius, Gilead, GBA Group, Gr\u00fcnenthal, GSK, Hexal, Johnson & Johnson, MSD, Novartis, onkowissen.de, Pfizer, Roche, UCB, and Viatris. Dr. Kiltz also serves on the Data Safety Monitoring Board for COPAGO and GWD. Yi-Ming Chen has no conflicts of interest to declare. Andrea Rubbert-Roth received honoraria for lectures and consultation from AbbVie, Amgen, Johnson & Johnson, MSD, Pfizer, Medac, UCB, Novartis, Sanofi, and Lilly. Sergio Fonseca, Jos\u00e9 Antunes, Arun Singh, Richard Milek, and Jordan Wu are employees of Johnson & Johnson and shareholders of Johnson & Johnson stock. Jeffrey A. Sparks has received research support from Boehringer Ingelheim, Bristol-Myers Squibb, Johnson & Johnson, and Sonoma Biotherapeutics unrelated to this work. Dr. Sparks has performed consultancy for AbbVie, Amgen, Anaptys, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Fresenius Kabi, Gilead, GSK, Inova Diagnostics, Invivyd, Johnson & Johnson, Merck, MustangBio, Novartis, Optum, Pfizer, ReCor, Sana, Sobi, and UCB unrelated to this work.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This narrative review is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors; formal ethics approval was not required.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}